{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:36:05Z","timestamp":1785551765716,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s00535-010-0240-6","type":"journal-article","created":{"date-parts":[[2010,4,12]],"date-time":"2010-04-12T09:06:54Z","timestamp":1271063214000},"page":"979-987","source":"Crossref","is-referenced-by-count":57,"title":["A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose\u2013response of tolvaptan in patients with decompensated liver cirrhosis"],"prefix":"10.1007","volume":"45","author":[{"given":"Kiwamu","family":"Okita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomasa","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Murawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"240_CR1","unstructured":"Guyton AC, Hall JE. Textbook of medical physiology. 10th ed. Philadelphia, PA: WB Saunders Company; 2000. p. 855\u20136."},{"issue":"3","key":"240_CR2","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","volume":"287","author":"Y Yamamura","year":"1998","unstructured":"Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287(3):860\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"240_CR3","first-page":"977","volume":"5","author":"SA Doggrell","year":"2004","unstructured":"Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5:977\u201383.","journal-title":"Curr Opin Investig Drugs"},{"key":"240_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1152\/ajprenal.00195.2005","volume":"290","author":"LC Costello-Boerrigter","year":"2006","unstructured":"Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:273\u20138.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"240_CR5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1172\/JCI106078","volume":"48","author":"FL Lieberman","year":"1969","unstructured":"Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), a fall in GFR during drug-induced diuresis. J Clin Invest. 1969;48(6):975\u201381.","journal-title":"J Clin Invest"},{"key":"240_CR6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1749-6632.1970.tb37014.x","volume":"170","author":"FL Lieberman","year":"1970","unstructured":"Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the \u201coverflow\u201d theory of ascites formation. Ann NY Acad Sci. 1970;170:202\u20136.","journal-title":"Ann NY Acad Sci"},{"key":"240_CR7","unstructured":"Levy M. Pathophysiology of ascites formation. In: Epstein M, editor. The kidney in liver disease. 2nd ed. New York: Elsevier, 1982. p. 245\u201380."},{"issue":"5","key":"240_CR8","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151\u20137.","journal-title":"Hepatology"},{"issue":"2","key":"240_CR9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, furosemide or hydrochlorothiazide. J Cardiovasc Phamacol. 2007;50(2):213\u201322.","journal-title":"J Cardiovasc Phamacol"},{"key":"240_CR10","unstructured":"Inuyama Symposium Kirokukannkoukai, editors. Proceedings of the 12th Inuyama Symposium: hepatitis A and fulminant hepatitis (in Japanese). Tokyo: Chugai Igakusha; 1982. p. 124."},{"issue":"21","key":"240_CR11","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","volume":"107","author":"M Gheorghiade","year":"2003","unstructured":"Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690\u20136.","journal-title":"Circulation"},{"issue":"12","key":"240_CR12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnet JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297(12):1332\u201343.","journal-title":"JAMA"},{"issue":"12","key":"240_CR13","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","volume":"297","author":"MA Konstam","year":"2007","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319\u201331.","journal-title":"JAMA"},{"key":"240_CR14","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u2013112.","journal-title":"N Engl J Med"},{"key":"240_CR15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/qjmed\/hcg159","volume":"96","author":"SH Lin","year":"2003","unstructured":"Lin SH, Hsu YJ, Chiu JS, Chu SJ, Davids MR, Halperin ML, et al. Osmotic demyelination syndrome: a potentially avoidable disaster. Q J Med. 2003;96:935\u201347.","journal-title":"Q J Med"},{"issue":"11 Suppl 1","key":"240_CR16","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","volume":"120","author":"JG Verbalis","year":"2007","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1\u201321.","journal-title":"Am J Med"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-010-0240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-010-0240-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-010-0240-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:09:09Z","timestamp":1740006549000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-010-0240-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1007\/s00535-010-0240-6","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}